Automated and Closed Cell Therapy Market by Product Type (Automated Cell Therapy, Closed Cell Therapy), by Application (Regenerative Medicine, Cancer Treatment, Cardiovascular Treatment, Autoimmune Diseases, Wound Healing), by End-User Industry (Healthcare & Medical, Pharmaceuticals, Biotechnology, Research & Academia, Contract Research Organizations, Hospitals & Clinics), and by Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Automated and Closed Cell Therapy Market was valued at USD 5.7 billion in 2023 and will surpass USD 13.7 billion by 2030; growing at a CAGR of 13.2% during 2024 - 2030.

The automated and closed cell therapy market is rapidly evolving, driven by significant advancements in biotechnologies and an increasing demand for personalized medicine. Cell therapies, which involve the manipulation of living cells to treat or cure diseases, are gaining traction due to their potential in treating a wide range of medical conditions, from cancer to autoimmune diseases. Automated systems in cell therapy are increasingly preferred for their precision, efficiency, and scalability, enabling higher-throughput production of cellular products. Meanwhile, closed systems are favored for maintaining sterility and reducing contamination risks during cell processing. This sector is poised for continued growth as regulatory frameworks evolve, supporting the development and commercialization of cell-based therapies.

Product Type: Automated Cell Therapy is Fastest Growing Owing to Technological Advancements

The automated cell therapy segment is growing at a remarkable pace, largely driven by advancements in technology and increasing demand for precision and scalability in cell-based treatments. Automation in cell therapy involves using advanced robotics and artificial intelligence to streamline cell processing and preparation, reducing human error and improving consistency in results. This has led to increased adoption in both clinical and industrial settings, as automated systems can process cells more efficiently and at scale. Additionally, automated systems allow for better reproducibility, which is crucial for the development of standardized therapies that can be administered across a larger patient population.

Automated systems are particularly beneficial in the manufacture of CAR-T (chimeric antigen receptor T-cell) therapies, which require precise engineering of patient cells to target and destroy cancer cells. As the demand for CAR-T therapies and other advanced cell therapies continues to grow, the market for automated cell therapy systems is expected to expand rapidly. The efficiency of automated systems in maintaining consistency, reducing labor costs, and increasing throughput is accelerating their adoption in the cell therapy market.

Application: Cancer Treatment is Largest Due to Increasing Demand for Advanced Therapies

Among the various applications of automated and closed cell therapies, cancer treatment stands as the largest subsegment. Cell-based therapies, such as CAR-T therapies, are revolutionizing cancer care by providing targeted and personalized treatments for patients with certain types of cancers, including lymphomas and leukemias. These therapies involve modifying the patient's own immune cells to better identify and destroy cancer cells. The success of CAR-T therapies has catalyzed further investment in cancer-related cell therapies, fueling their growth in the market.

The growing incidence of cancer globally, coupled with the need for more effective treatments beyond traditional chemotherapy, is driving the widespread adoption of cancer cell therapies. As more cancer patients become eligible for cell-based treatments, especially those with refractory or relapsed cancers, the demand for automated and closed systems capable of producing personalized therapies at scale will continue to grow. This makes cancer treatment the largest application segment in the automated and closed cell therapy market.

End-User Industry: Healthcare & Medical is Largest Owing to Rising Demand for Innovative Therapies

The healthcare & medical sector remains the largest end-user industry for automated and closed cell therapy, driven by the growing demand for innovative therapies and the increasing prevalence of diseases requiring advanced treatments. Hospitals, clinics, and diagnostic centers are at the forefront of adopting these technologies, particularly in areas like regenerative medicine and cancer treatment. The healthcare industry is increasingly focused on personalized medicine, which relies heavily on cell-based therapies for targeting specific patient needs.

As healthcare systems worldwide seek to improve patient outcomes through advanced treatment options, the use of automated and closed cell therapy systems is becoming indispensable. These technologies provide significant advantages, such as reduced treatment times, improved accuracy, and the ability to handle large volumes of treatments. With the healthcare industry expanding rapidly in both developed and emerging markets, the demand for cell therapies, especially in hospital and clinical settings, is expected to continue its upward trajectory.

Region: North America is Largest Owing to Advanced Healthcare Infrastructure

North America holds the largest share of the automated and closed cell therapy market, primarily due to the region's advanced healthcare infrastructure, strong investment in research and development, and supportive regulatory environments. The U.S., in particular, is a leader in adopting innovative cell-based therapies, driven by major pharmaceutical and biotechnology companies, along with leading academic and research institutions. The FDA's favorable stance on regenerative medicine and advanced therapy medicinal products (ATMPs) has further accelerated the commercialization of cell therapies in the region.

The presence of major players like Gilead Sciences, Novartis, and Kite Pharma, along with an established network of clinical trial facilities and cutting-edge research labs, has reinforced North America's dominance in the market. Additionally, the region's high healthcare spending and growing demand for personalized and targeted treatments ensure that North America remains the largest market for automated and closed cell therapy solutions.

Competitive Landscape: Leading Companies Driving Innovation and Market Growth

The automated and closed cell therapy market is highly competitive, with several global companies playing a significant role in the development and commercialization of cell-based therapies. Leading players in the market include Gilead Sciences, Novartis, Kite Pharma (a Gilead Company), Stryker Corporation, Mesoblast, and Lonza Group. These companies are at the forefront of developing innovative therapies, including CAR-T cell therapies and other advanced immunotherapies, and are leveraging automated and closed systems to streamline production and improve patient outcomes.

The competitive landscape is further shaped by strategic partnerships, collaborations, and mergers & acquisitions as companies seek to expand their product portfolios and strengthen their positions in the market. Research and development activities are crucial for staying ahead in the rapidly evolving cell therapy market, and these companies continue to invest heavily in technological advancements to meet growing demand. With strong regulatory support and increasing healthcare spending globally, these companies are poised to drive the future growth of the automated and closed cell therapy market.

Recent Developments:

• Gilead Sciences Completes Acquisition of Forty Seven, Inc. – Gilead Sciences acquired Forty Seven, Inc. to strengthen its immuno-oncology pipeline, enhancing its position in cell therapy solutions, particularly for cancer treatments.
• Novartis Announces Expansion of CAR-T Cell Therapy Manufacturing – Novartis unveiled its new CAR-T manufacturing facility, enhancing its production capabilities for personalized cell therapies used in cancer treatment.
• Lonza Group Collaborates with Cell Therapies to Expand Manufacturing – Lonza Group entered into a partnership with Cell Therapies to expand the manufacturing of closed cell therapies, providing enhanced production capabilities for cell-based treatments.
• Kite Pharma Receives FDA Approval for New CAR-T Cell Therapy – Kite Pharma, a Gilead company, received FDA approval for its innovative CAR-T therapy, revolutionizing cancer treatment by providing patients with personalized cell-based therapies.
• Fujifilm Cellular Dynamics Expands Stem Cell Production Capacity – Fujifilm Cellular Dynamics expanded its stem cell production facilities to meet the growing demand for advanced therapies, reinforcing its position in the automated cell therapy market.

List of Leading Companies:

• Novartis AG
• Gilead Sciences
• Bayer AG
• Stryker Corporation
• Kite Pharma (A Gilead Company)
• Lonza Group
• Celyad
• Mesoblast Limited
• Celgene Corporation (Acquired by Bristol-Myers Squibb)
• Bluebird Bio
• Stemline Therapeutics
• Kiadis Pharma
• Orchard Therapeutics
• TCR2 Therapeutics
• Fujifilm Cellular Dynamics

Report Scope: